Biocon Limited · NSE:BIOCON
Biocon — Biocon Biologics — Investor Presentation (September 2024)
30 slides from Biocon's investor presentation, Sep 23, 2024
Slide 1: Exchange filing cover letter: Corporate Presentation
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423 CIN: L24234KA1978PLC003417 www.biocon.com BIO/SECL/SP/2024-25/94 September 23, 2024 To, To, The Manager The Manager BSE Limited National Stock Exchange of India Limited Department of Cor
Slide 2: Corporate Presentation Biocon Biologics Limited
INTERNAL Corporate Presentation Biocon Biologics Limited September 2024 Transforming Healthcare. Transforming Lives. PRIVILEGED AND CONFIDENTIAL 0
Slide 3: Disclaimer
INTERNAL Disclaimer This presentation and the accompanying slides (the “presentation”) contain selected information about the activities of Biocon Biologics Limited (the “Company”) and its subsidiaries and affiliates (together, the “Group”) as at the date of the presentation. It does not purport to
Slide 4: Disclaimer
INTERNAL Disclaimer This presentation does not constitute or form part of any offer to purchase, a solicitation of an offer to purchase, an offer to sell or an invitation or solicitation of an offer to sell, issue or subscribe for, securities in or into the United States or in any other jurisdiction
Slide 5: Disclaimer
INTERNAL Disclaimer Unless stated otherwise, industry and market data in this presentation has been obtained through internal company research, management estimates and industry and general publications. Management estimates are based on publicly- available information released by third-party source
Slide 6: Agenda
INTERNAL Agenda 1 Group Overview – Biocon Limited 5 2 Industry Overview – Biologics and Biosimilars 9 43 Company Overview – Biocon Biologics Limited 16 Transforming Healthcare. Transforming Lives. PRIVILEGED AND CONFIDENTIAL 4
Slide 7: Biocon Group at a Glance
INTERNAL Biocon Group at a Glance 120+ Founded in 1978 and headquartered in Bangalore, India Countries where Biocon products are available1 Listed in 2004 with a current market cap of USD 5.3bn2 One of the first, fully integrated global biopharmaceutical companies out of India 100+ Cutting-e
Slide 8: Leading Global Pharmaceutical Company
INTERNAL Leading Global Pharmaceutical Company Has well-diversified operations and vertically integrated capabilities Market cap of c. USD 5.3bn7 Biosimilars Generics Research Services Novel Biologics Expanding access through Ensuring access Partnering to deliver Pushing scientific innovative, inclu
Slide 9: Biocon Ownership Organization Structure
INTERNAL Biocon Ownership Organization Structure Biocon Limited Consolidated Shareholding (June 30, 2024) Market Cap1: USD 5,262mn 19% Promoter Revenue2 (FY24): USD 1,769mn 61% Institutions EBITDA (FY24): USD 499mn 20% Total Debt3 (June 30, 2024): USD 1,487mn Others Cash4 (June 30, 2024): USD 355mn
Slide 10: Agenda
INTERNAL Agenda 1 Group Overview – Biocon Limited 5 2 Industry Overview – Biologics and Biosimilars 9 43 Company Overview – Biocon Biologics Limited 16 Transforming Healthcare. Transforming Lives. PRIVILEGED AND CONFIDENTIAL 8
Slide 11: Global Pharmaceutical Market Overview
INTERNAL Global Pharmaceutical Market Overview Steadily growing global pharmaceutical market with biologics representing an increasing share Global pharmaceutical market size1 (USD bn) Top global therapeutic areas by projected global spending 2018-28E Biologics CAGR = 10%, 1,612 500 Small molecule d
Slide 12: Biosimilars are a Major Component of the Global Pharmaceutical Market
INTERNAL Biosimilars are a Major Component of the Global Pharmaceutical Market Use of Biologics in Key Therapeutic Areas1 Upcoming Biosimilar Opportunities For Key Molecules2 Share of biologics Standard biologics Therapeutic treatments Molecule Brand Name Peak sales (USD bn) Indication treatment opt
Slide 13: What is a Biosimilar?
INTERNAL What is a Biosimilar? Comparison of biosimilars and generics in development costs and capabilities required Biosimilars Small molecule generics Large, complex molecules produced from Small, chemically synthesized molecules that Definition living organisms that are highly similar to the
Slide 14: Biosimilars Opportunity Potential
INTERNAL Biosimilars Opportunity Potential Vey large opportunity with 45+ blockbusters1 (est. peak annual sales of ~USD 270 bn) expected to lose exclusivity by 2032 Cumulative global annual peak sales USD bn Actual Projected 85 BBL Portfolio 65 coverage more than 50% in all major areas of 45 opportu
Slide 15: Global Biosimilars Market Overview
INTERNAL Global Biosimilars Market Overview US and Europe continue to be the two largest biosimilars markets across the globe Global biosimilars market size Key growth drivers and trends in the global biosimilars market ✓ An abundance of biologics reaching LOEs USD bn ✓ Increasing incidence levels (
Slide 16: Overview of Competitive Landscape
INTERNAL Overview of Competitive Landscape 4 cohorts of peers illustrated – Originators, biosimilar-focused, generics, and R&D-focused peers(1) Our Originator peers Our Biosimilar-focused peers Acquired Viatris Building R&D & Building up own Remains invested in Dropped early-stage pipeline biosimila
Slide 17: Agenda
INTERNAL Agenda 1 Group Overview – Biocon Limited 5 2 Industry Overview – Biologics and Biosimilars 9 43 Company Overview – Biocon Biologics Limited 16 Transforming Healthcare. Transforming Lives. PRIVILEGED AND CONFIDENTIAL 15
Slide 18: Biocon Biologics at a Glance
INTERNAL Biocon Biologics at a Glance Global reach in Top 5 Top 15 80+ Diverse global talent 120+ global insulin in global cGMP approvals pool of ~5,000 countries including player2 biomanufacturing received from key people U.S., Europe and capacity1 regulatory agencies Emerging Markets Portfolio com
Slide 19: Biosimilars Value Chain / Acquisition of Viatris' Global Biosimilars Business
INTERNAL USD 3bn+ Acquisition of Viatris’ Global Biosimilars Business One of the largest outbound pharma deals in India Sources of Acquisition (USD mn) Transformational deal to create value for all stakeholders Syndicated Term Transformational Successfully integrated the 1,200 Builds on a decade lon
Slide 20: Leading Biopharma Player with Fully Vertically Integrated Capabilities and Global Footprint
INTERNAL Leading Biopharma Player with Fully Vertically Integrated Capabilities and Global Footprint 1 ✓ Comprehensive portfolio of biosimilars creating well-diversified revenue streams 2 ✓ Strong pipeline assets in strategically focused therapeutic areas ✓ Proven R&D capabilities backed by cutting-
Slide 21: Comprehensive Portfolio of Biosimilars Creating Well-diversified Revenue Streams (I)
INTERNAL 1 Comprehensive Portfolio of Biosimilars Creating Well-diversified Revenue Streams (I) Diverse portfolio of 8 biosimilars targeting some of the biologics globally Oncology Immunology Diabetes Commercialized Products bPegfilgrastim bTrastuzumab3 bBevacizumab bAdalimumab bEtanercept4 Glargine
Slide 22: Comprehensive Portfolio of Biosimilars Creating Well-diversified Revenue Streams (II)
INTERNAL 1 Comprehensive Portfolio of Biosimilars Creating Well-diversified Revenue Streams (II) Industry leading portfolio and an early entrant into biosimilars Trastuzumab ✓ ✓ ✓ ✓ ✓ ✓ Bevacizumab ✓ ✓ ✓ ✓ ✓ ✓ ✓ Pegfilgrastim ✓ ✓ ✓ ✓ Oncology Filgrastim ✓ ✓ Pertuzumab ✓ Rituximab ✓ ✓ ✓ ✓ ✓ Adalimuma
Slide 23: Strong Pipeline Assets in Strategically Focused Therapeutic Areas
INTERNAL 2 Strong Pipeline Assets in Strategically Focused Therapeutic Areas Robust in-house R&D capabilities with a pipeline of 4 late-stage and 8 early-stage assets coupled with 300+ active patents globally Peak sales1 Peak sales1 c.USD 10bn c.USD 7bn 2 undisclosed assets in Ophthalmology Bone hea
Slide 24: Proven R&D Capabilities Backed by Cutting-edge Science and Technology
INTERNAL 3 Proven R&D Capabilities Backed by Cutting-edge Science and Technology Continued investment in R&D is key drive of long-term growth Achieved many firsts in the global biosimilar space Invested > USD 1bn in R&D of biosimilars ahead of its peers to build 1st company to develop rh-Insulin o
Slide 25: State-of-the-Art Manufacturing Facilities with the Highest Quality Standards
INTERNAL 4 State-of-the-Art Manufacturing Facilities with the Highest Quality Standards State-of-the-art global scale manufacturing facilities Comprehensive manufacturing capabilities Drug substance Drug product Devices Insulins Sterile injectables ‒ Vials Monoclonal Reusable pens1 antibodie
Slide 26: Global Commercial Presence Developed via Strong In-house Team and Reputable Partnerships
INTERNAL 5 Global Commercial Presence Developed via Strong In-house Team and Reputable Partnerships Strong commercial presence and established network of robust partnerships.. …leading to significantly improved market position across the World Volume market shares for BBL’s commercial products in th
Slide 27: Global Board of Directors with Diverse Expertise and Experience
INTERNAL 6 Global Board of Directors with Diverse Expertise and Experience Kiran Mazumdar-Shaw Shreehas Tambe Arun Chandavarkar Bobby Parikh Dan Bradbury Peter Piot Nicholas Haggar Executive Chairperson CEO & MD Non-Executive, Non- Independent Director Independent Director Independent Director Indep
Slide 28: Experienced Global Leadership Team with Robust Execution Capabilities
INTERNAL 6 Experienced Global Leadership Team with Robust Execution Capabilities and In- depth Industry Knowledge Kiran Mazumdar-Shaw Shreehas Tambe Executive Chairperson Chief Executive Officer and Managing Director ◆ Chairperson of the Board of Directors since inception ◆ Member of the Board of Di
Slide 29: Biocon Biologics – Capital Structure
INTERNAL 7 Biocon Biologics – Capital Structure BBL Capital Structure4 Snapshot of diversified bank lender base Capital Structure Table (Jun’24) USD mn Equity and Structured Instruments 2,666 International Banks Total Equity and Structured Instruments 2,666 Acquisition Debt (Syndicated Term Loan) 95
Slide 30: Thank You
INTERNAL Thank You Transforming Healthcare. Transforming Lives. PRIVILEGED AND CONFIDENTIAL 28
Biocon Biologics — Investor Presentation (September 2024) on 6ix